Form 4: Integra LifeSciences CHRO Receives RSU Grant

Integra LifeSciences Holdings Corp's EVP & CHRO, Chantal Veillon-Berteloot, was granted 41,783 Restricted Stock Units and disposed of 5,420 common shares.

Summary

• Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), was granted 41,783 Restricted Stock Units (RSUs) on March 11, 2026.
• These RSUs will vest over three years: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the grant date.
• Concurrently, Veillon-Berteloot disposed of 5,420 shares of common stock at a price of $9.61 per share on March 11, 2026.
• Following these transactions, Veillon-Berteloot beneficially owns 22,227 shares of common stock and 41,783 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting ongoing executive incentive alignment and retention efforts, which are generally favorable for corporate stability and long-term strategy execution.

Positives

• Grant of 41,783 Restricted Stock Units to a key executive aligns management's interests with long-term shareholder value.
• The vesting schedule encourages executive retention over a three-year period.

Negatives

• The disposition of 5,420 common shares, likely for tax purposes related to equity compensation, reduces the executive's direct common stock holdings.

Future Outlook

The Restricted Stock Unit award has a three-year vesting schedule, with 33% vesting on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, indicating a long-term incentive for the executive.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units is a standard practice in executive compensation across the medical technology and life sciences sectors, aiming to align executive incentives with long-term company performance and shareholder value. The disposition of shares at $9.61 is likely a tax-related transaction common with RSU vesting.

Comparison to Industry Standards

• This RSU grant and vesting schedule is consistent with typical executive compensation packages in the medical device and life sciences industry, which often use long-term equity incentives to retain key talent and motivate performance.
• Similar multi-year vesting schedules are observed at companies like Medtronic or Stryker for their senior executives, though the specific number of units would vary based on company size and executive role.

Related Party Transactions

• The transaction involves an executive and the company, which is a related party transaction, but it is a standard compensation event. No unusual related party dealings are disclosed beyond the executive compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term shareholder value, potentially fostering sustained performance. The disposition of shares is a minor reduction in direct holdings.
• Employees: No direct impact on general employees is indicated, but it reflects the company's executive compensation strategy.

Next Steps

• 33% of the granted Restricted Stock Units will vest on March 11, 2027.
• Another 33% of the granted Restricted Stock Units will vest on March 11, 2028.
• The remaining 34% of the granted Restricted Stock Units will vest on March 11, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and a related tax-driven stock disposition. While the RSU grant is a positive for executive alignment, it does not present new information that would fundamentally alter the investment thesis for Integra LifeSciences. It's a standard operational disclosure, suggesting no immediate catalyst for a "buy" or "sell" recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market trends.

Keywords

Integra LifeSciences, IART, Form 4, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Chantal Veillon-Berteloot, EVP & CHRO, stock disposition